ChromaDex Looks To Pharma Model For Commercializing Supplement Research
This article was originally published in The Tan Sheet
Nutritional ingredient developer ChromaDex is employing a pharma-style business model to expand its R&D into finished dietary supplements – with a long-term eye on pharmaceutical products. The firm’s recent hire of CEO Jeffrey Himmel was a significant step into the consumer products arena.
You may also be interested in...
Himmel named ChromaDex CEO; Pinney reorganizes senior management; FDA vet Chappell jumps to Greenleaf; more People In Brief.
GlaxoSmithKline's decision to abandon its pharmaceutical research program on resveratrol leaves the red wine extract exclusively to the nutritionals industry.
Omega-3 fish oils, once exclusive to the realm of dietary supplements, increasingly are swimming upstream into prescription drugs – a trend with both positive and negative implications for supplements.